[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1123401T1 - Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων - Google Patents

Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων

Info

Publication number
CY1123401T1
CY1123401T1 CY20201100603T CY201100603T CY1123401T1 CY 1123401 T1 CY1123401 T1 CY 1123401T1 CY 20201100603 T CY20201100603 T CY 20201100603T CY 201100603 T CY201100603 T CY 201100603T CY 1123401 T1 CY1123401 T1 CY 1123401T1
Authority
CY
Cyprus
Prior art keywords
compounds
kinase inhibitors
compounds useful
carboxamide compounds
indole carboxamide
Prior art date
Application number
CY20201100603T
Other languages
English (en)
Inventor
Saleem Ahmad
Joseph A. Tino
John E. Macor
Andrew J. Tebben
Hua Gong
Qingjie Liu
Douglas G. Batt
Khehyong Ngu
Scott Hunter Watterson
Weiwei Guo
Myra Beaudoin Bertrand
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1123401T1 publication Critical patent/CY1123401T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αποκαλύπτονται ενώσεις του Χημικού Τύπου (Ι): ή ένα άλας εξ αυτών, όπου: το Χ είναι CR4 ή Ν· τα R1, R2, R3, R4, και Α καθορίζονται εις το παρόν. Επίσης αποκαλύπτονται και μέθοδοι χρήσης τέτοιων ενώσεων ως αναστολείς της κινάσης τυροσίνης του Bruton (Btk), και φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις. Αυτές οι ενώσεις είναι χρήσιμες σε αγωγή, πρόληψη, ή επιβράδυνση της προόδου των παθήσεων ή διαταραχών σε μια ποικιλία θεραπευτικών περιοχών, όπως είναι οι αυτοάνοσες παθήσεις και οι αγγειακή πάθηση.
CY20201100603T 2014-10-24 2020-06-30 Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων CY1123401T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
PCT/US2015/057055 WO2016065226A1 (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhobitors

Publications (1)

Publication Number Publication Date
CY1123401T1 true CY1123401T1 (el) 2021-12-31

Family

ID=54427877

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20201100603T CY1123401T1 (el) 2014-10-24 2020-06-30 Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY20201100747T CY1123395T1 (el) 2014-10-24 2020-08-11 Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100747T CY1123395T1 (el) 2014-10-24 2020-08-11 Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων

Country Status (34)

Country Link
US (8) US9688629B2 (el)
EP (2) EP3461821B1 (el)
JP (1) JP6517928B2 (el)
KR (2) KR102030305B1 (el)
CN (2) CN110511209B (el)
AR (2) AR102426A1 (el)
AU (2) AU2015335694B2 (el)
CA (1) CA2965517C (el)
CL (1) CL2017000992A1 (el)
CO (1) CO2017004481A2 (el)
CY (2) CY1123401T1 (el)
DK (2) DK3209656T3 (el)
EA (2) EA032277B1 (el)
ES (2) ES2809974T3 (el)
HR (2) HRP20200819T1 (el)
HU (2) HUE050706T2 (el)
IL (2) IL251797B (el)
LT (2) LT3461821T (el)
MA (2) MA40301B1 (el)
ME (2) ME03807B (el)
MX (2) MX2020008024A (el)
MY (2) MY195561A (el)
PE (2) PE20190710A1 (el)
PH (2) PH12017500725B1 (el)
PL (2) PL3461821T3 (el)
PT (2) PT3209656T (el)
RS (2) RS60312B1 (el)
SG (3) SG10201903579SA (el)
SI (2) SI3461821T1 (el)
TN (2) TN2017000119A1 (el)
TW (2) TWI743401B (el)
UY (1) UY36371A (el)
WO (1) WO2016065226A1 (el)
ZA (1) ZA201804893B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6243003B2 (ja) 2013-03-15 2017-12-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
ES2784846T3 (es) 2014-04-23 2020-10-01 Incyte Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET
BR112017007563A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co compostos atropisômeros tricíclicos
DK3209651T3 (da) 2014-10-24 2020-02-03 Bristol Myers Squibb Co Carbazolderivater
EP3210973B1 (en) 2014-10-24 2020-12-02 Takeda Pharmaceutical Company Limited Heteroaryl compounds for the treatment of ophthalmic diseases
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
PE20240236A1 (es) 2016-06-20 2024-02-16 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
LT3507282T (lt) * 2016-09-02 2021-01-25 Bristol-Myers Squibb Company Indolinių karboksamido junginių gamybos būdas
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
EP3533451B1 (en) 2017-01-21 2022-07-27 Guangzhou Hanfang Pharmaceuticals Co., Ltd. Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
EP3694528A4 (en) 2017-10-13 2021-07-28 The Regents of the University of California MTORC1 MODULATORS
PT3752501T (pt) 2018-02-13 2023-07-12 Gilead Sciences Inc Inibidores de pd-1/pd-l1
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
AU2019301811B2 (en) * 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
AU2020398840A1 (en) * 2019-12-04 2022-05-26 Aptinyx Inc. Methods of treating cognitive impairment associated with neurodegenerative disease
CN115867346A (zh) * 2020-06-02 2023-03-28 Gb005股份有限公司 激酶抑制剂
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022035799A1 (en) * 2020-08-10 2022-02-17 Prelude Therapeutics Incorporated Heterocycle cdk inhibitors and their use thereof
PE20230855A1 (es) 2020-08-14 2023-05-29 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos
WO2022089620A1 (zh) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 吲哚基甲酰胺类化合物的新晶型及其制备方法
KR20230131251A (ko) * 2021-01-12 2023-09-12 쥐비005 인코포레이티드 키나아제 억제제로서의 인돌 유도체
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
CN116348453A (zh) * 2021-04-25 2023-06-27 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023034732A1 (en) 2021-08-30 2023-03-09 Bristol-Myers Squibb Company Compound useful for pet-imaging of bruton's tyrosine kinase
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
AR130094A1 (es) 2022-08-03 2024-10-30 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0517211B8 (pt) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa composto, composição farmacêutica e seu uso.
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
WO2006106326A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
EP1896014A4 (en) * 2005-06-30 2010-07-21 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
US8263648B2 (en) 2006-09-11 2012-09-11 Mylan Laboratories Ltd. Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PT2526771T (pt) 2006-09-22 2017-02-27 Pharmacyclics Llc Inibidores de tirosina-cinase de bruton
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
CN101687036A (zh) 2007-04-27 2010-03-31 阿斯利康(瑞典)有限公司 治疗恶性血液病的chk1抑制剂与b细胞耗尽抗体
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
EP2231143B1 (en) 2007-12-13 2013-07-03 Merck Sharp & Dohme Corp. 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES
PT2247558T (pt) 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (en) 2009-02-13 2010-08-19 Nextivity, Inc. Remote control for booster
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CN105330675A (zh) 2010-11-15 2016-02-17 Viiv保健英国有限公司 Hiv复制的抑制剂
JP2014518853A (ja) 2011-04-28 2014-08-07 ブリストル−マイヤーズ スクイブ カンパニー 新規な二環式窒素含有ヘテロアリールｔｇｒ５受容体調節因子
EP2709997B1 (en) 2011-05-17 2016-06-29 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
ES2660210T3 (es) * 2012-09-07 2018-03-21 Novartis Ag Derivados de indolcarboxamida y usos de los mismos
WO2014210087A1 (en) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
NZ754039A (en) * 2013-06-26 2021-06-25 Abbvie Inc Primary carboxamides as btk inhibitors

Also Published As

Publication number Publication date
EA034931B1 (ru) 2020-04-08
IL262206A (en) 2018-11-29
CL2017000992A1 (es) 2017-11-17
KR20180132167A (ko) 2018-12-11
LT3461821T (lt) 2020-08-10
AR102426A1 (es) 2017-03-01
ZA201804893B (en) 2020-07-29
CN107108583B (zh) 2020-11-13
US11623921B2 (en) 2023-04-11
SG10201903578VA (en) 2019-05-30
SI3461821T1 (sl) 2020-09-30
JP6517928B2 (ja) 2019-05-22
MY188048A (en) 2021-11-12
KR102030305B1 (ko) 2019-10-08
TW201900612A (zh) 2019-01-01
PE20170695A1 (es) 2017-05-26
US20190248760A1 (en) 2019-08-15
HRP20200819T1 (hr) 2020-08-07
IL262206B (en) 2020-07-30
RS60312B1 (sr) 2020-07-31
US9920031B2 (en) 2018-03-20
US9688629B2 (en) 2017-06-27
EP3461821B1 (en) 2020-05-13
EP3461821A1 (en) 2019-04-03
EA201790740A1 (ru) 2017-08-31
SG10201903579SA (en) 2019-05-30
PL3461821T3 (pl) 2020-10-19
BR112017007956A2 (pt) 2017-12-19
MX2017005259A (es) 2017-07-26
EA032277B1 (ru) 2019-05-31
PH12020500265A1 (en) 2021-02-22
US20230192645A1 (en) 2023-06-22
US9802915B2 (en) 2017-10-31
RS60629B1 (sr) 2020-09-30
IL251797B (en) 2020-07-30
MA40301B1 (fr) 2019-12-31
TN2018000218A1 (en) 2019-10-04
NZ731946A (en) 2021-02-26
US20160115126A1 (en) 2016-04-28
CA2965517C (en) 2023-05-02
US20170260160A1 (en) 2017-09-14
CN107108583A (zh) 2017-08-29
DK3209656T3 (da) 2020-07-13
EP3209656A1 (en) 2017-08-30
DK3461821T3 (da) 2020-08-17
US20200165222A1 (en) 2020-05-28
LT3209656T (lt) 2020-07-27
CA2965517A1 (en) 2016-04-28
HUE050706T2 (hu) 2020-12-28
TW201630880A (zh) 2016-09-01
SI3209656T1 (sl) 2020-07-31
ME03807B (me) 2021-04-20
KR102001745B1 (ko) 2019-07-18
SG11201703188QA (en) 2017-05-30
AR120317A2 (es) 2022-02-09
TN2017000119A1 (en) 2018-07-04
ME03740B (me) 2021-01-20
EA201892207A1 (ru) 2019-02-28
IL251797A0 (en) 2017-06-29
PT3209656T (pt) 2020-06-08
US10604504B2 (en) 2020-03-31
CY1123395T1 (el) 2021-12-31
MA40301A1 (fr) 2019-03-29
TWI743401B (zh) 2021-10-21
AU2015335694B2 (en) 2020-04-02
MA47043B1 (fr) 2021-09-30
HRP20201146T1 (hr) 2020-10-30
PE20190710A1 (es) 2019-05-17
ES2795366T3 (es) 2020-11-23
KR20170061175A (ko) 2017-06-02
JP2017531679A (ja) 2017-10-26
CN110511209A (zh) 2019-11-29
ES2809974T3 (es) 2021-03-08
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
WO2016065226A8 (en) 2017-04-27
AU2019283921A1 (en) 2020-01-16
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
CO2017004481A2 (es) 2017-08-10
TWI744218B (zh) 2021-11-01
MX2020008024A (es) 2022-06-10
UY36371A (es) 2016-04-29
EP3209656B1 (en) 2020-04-01
MY195561A (en) 2023-02-02
US20210107891A1 (en) 2021-04-15
HUE050592T2 (hu) 2020-12-28
US10329274B2 (en) 2019-06-25
AU2015335694A1 (en) 2017-06-08
AU2019283921B2 (en) 2021-01-07
MA47043A1 (fr) 2021-03-31
WO2016065226A1 (en) 2016-04-28
US20190119245A1 (en) 2019-04-25
PT3461821T (pt) 2020-08-05
CN110511209B (zh) 2022-07-05

Similar Documents

Publication Publication Date Title
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY1124478T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1122549T1 (el) Παραγωγα καρβαζολης
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CY1126109T1 (el) Αναστολεις toy trpc6
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CY1119371T1 (el) Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
CY1124970T1 (el) Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
EA201790870A1 (ru) Трициклические атропоизомерные соединения
EA201990400A1 (ru) Соединения и композиции и их применение
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA202190787A1 (ru) Пиридазиноны и способы их применения
UA123899U (uk) Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази